Anti-carbamylated protein antibody in Inflammatory Disease

• Research type

  Research Study

• Full title

  Anti-carbamylated protein antibody in Rheumatoid Arthritis associated Interstitial Lung Disease and other inflammatory conditions including plasma cell dyscrasias

• IRAS ID

  312912

• Contact name

  Paul Minnis

• Contact email

  paul.minnis@northerntrust.hscni.net

• Sponsor organisation

  NHSCT

• ISRCTN Number

  ISRCTN00000000

• Clinicaltrials.gov Identifier

  NCT00000000

• Duration of Study in the UK

  0 years, 5 months, 2 days

• Research summary

  Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting about 0.5–1% of the northern hemisphere.1 Extra-articular manifestations are prevalent, with the lungs being the most common site,2 and interstitial lung disease (ILD) being the most severe form of pulmonary involvement. In some studies, the median survival of patients with rheumatoid arthritis and a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) is around 3 years.3+4
  Currently, serological markers including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are widely used to assist in the diagnosis of RA.5 High serum levels of these autoantibodies can be present for up to 5 years before the clinical onset of arthritis.6 New serologic markers are being investigated, however 30% of RA patients remain seronegative. Anti-carbamylated proteins antibodies (anti-CarP) and antibodies against peptidyl-arginine deiminase type four (anti-PAD4) have been investigated as novel markers of RA.7+8Recent evidence suggests a strong association between anti-CarP and ILD.9

• REC name

  North of Scotland Research Ethics Committee 2

• REC reference

  22/NS/0042

• Date of REC Opinion

  25 Mar 2022

• REC opinion

  Favourable Opinion